Aim: Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to reduce major cardiovascular events. However, its cost is relatively higher than other oral antidiabetic drugs. This study aims to compare the costs and benefits of liraglutide vs sitagliptin, in treating T2DM in Thailand. Methods: This study consists of two parts. In part 1, the cost of keeping T2DM under control per patient (HbA1c<7.0% with no reported hypoglycemia and no body weight gain) with liraglutide (1.2 and 1.8 mg daily) was compared with using sitagliptin (100 mg daily). Costs were based on Thai local data. Clinical outcomes were based on head-to-head randomized controlled trials. Part 2 estimated the cost-per-controlled patient, based on major cardiovascular outcomes (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). Economic benefit was calculated as the reduction in cardiovascular outcomes. Results: In Thailand, liraglutide (1.8 mg daily) costs 7.37-times more than sitagliptin 100 mg. The cost per patient achieving a composite clinical endpoint (HbA1c<7.0%, with no weight gain and no hypoglycemic events) in patients with T2DM receiving liraglutide 1.8 mg is 2.80-times higher than patients receiving sitagliptin 100 mg. When cardiovascular benefits (reduced composite endpoint of major cardiovascular events, ie, cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) were taken into account, it was found that liraglutide had lower cost than sitagliptin, resulting in estimated savings of 20,085 THB (620 USD) per patient per year. Conclusion: The clinical benefits of liraglutide (HbA1c<7.0%, no hypoglycemia, no weight gain, reduced cardiovascular outcomes) partly offset its high price. Therefore, liraglutide should be considered as an appropriate treatment alternative to sitagliptin, particularly for T2DM patients with high cardiovascular risks.
Introduction
The current pandemic of diabetes mellitus and the projected future growth of the prevalence of the disease constitute a global public health crisis. Furthermore, increasingly unhealthy lifestyles, attributed to poor diets, immobility, and the growing prevalence of obesity in developing countries, are contributing to its increased occurrence. 1, 2 For example, from 2009 to 2014, diabetes prevalence amongst ≥15 year-olds increased from 6.9 to 8.9% (National Health Examination Survey (NHES) IV and NHES V, respectively mortality rates of diabetes patients per 100,000 population almost doubled from 12.1 to 22.3, 4 putting the disease among the top ten leading causes of death in the country. As the number of diabetes patients increases in Thailand, the costs of the disease and its complications have also increased. 5 The average annual healthcare cost of a diabetic patient was USD 881.47 in 2008 or 948.57 presented in 2018 USD (which has increased to 956.16 in 2018), amounting to 21% of gross domestic product per capita. Complications from the disease increase costs substantially. Informal care, defined as the care provided by people from a care recipient's social network such as family, friends, neighbors, 6 accounts for a greater percentage of overall costs than medical treatment (28% vs 23%), 7 indicating a substantial economic impact on patients' families. Therefore, effective interventions or initiatives are urgently needed to reduce both the incidence and the financial impact of the disease, as well as improve patients' quality-of-life.
Liraglutide is a glucagon-like peptide-1 (GLP-1) agonist. It is an effective antidiabetic drug that does not cause weight gain, a common side-effect associated with several other commonly used antidiabetic drugs. 8 The drug provides greater glycemic control and weight reduction in T2DM patients than sitagliptin does. 9, 10 Moreover, it reduces the incidence of cardiovascular diseases and mortality of T2DM patients who have high cardiovascular risks, compared with placebo and other anti-diabetic drugs. 11, 12 Although liraglutide is a relatively new and premium drug, the benefits from its use could potentially outweigh its high price. Hence, the study presented here was aimed at comparing the costs and benefits of using liraglutide to treat T2DM patients in Thailand with using sitagliptin for the same purpose.
Subjects, materials, and methods

Scope of the study
There were two parts to this study. Part 1 addressed the cost of achieving glycemic control in T2DM patients, whilst part 2 expanded to evaluate the impact that preventing adverse cardiovascular outcomes had on total cost of care. Part 1 determined the average annual cost per patient of achieving the clinically relevant composite endpoint that indicates control of the disease: HbA1c<7.0%, no reported hypoglycemia, and no body weight gain. 9, 10 The treatments compared were daily doses of liraglutide (1.2 mg or 1.8 mg daily) or sitagliptin (100 mg daily).
The cost of control model was developed using Microsoft Excel. The time horizon was 52 weeks, based on the clinical outcomes from the clinical trial. Consequently, discounting was not considered in the study. Part 2 extended the study to include the costs of cardiovascular outcomes in a cost-benefit comparison between liraglutide (1.8 mg daily) and sitagliptin (100 mg daily). The cost-per-controlled-patient was the medication cost of the significant adverse cardiovascular outcomes, including reduced composite endpoint events (cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke), death from cardiovascular causes, and myocardial infarction. In addition, the economic benefits arising from the prevention of such outcomes were also calculated.
Treatment strategies
During part 1 of the study, we compared liraglutide 1.8 mg or 1.2 mg, administered by a once-daily subcutaneous injection, with sitagliptin 100 mg, taken orally also once daily; whilst, in part 2, the benefits of subcutaneous liraglutide (1.8 mg daily only) were compared with those of oral sitagliptin (100 mg daily).
Treatment cohorts
The cohort population used in part 1 of the study consisted of T2DM patients who had inadequate glycemic control (HbA1c>7.5%), whilst those used for part 2 consisted of T2DM patients at high risk of cardiovascular diseases.
Clinical data
In part 1 of the study, the proportions of T2DM patients achieving the composite endpoint, which indicates control of the disease, were obtained from the 1860-LIRA-DPP4 trial (ClinicalTrial.gov Identifier: NCT00700817) published in 2010-2011. 9, 10 In brief, this head-to-head rando- The clinical data, used in part 2 of the study, were from two large previous studies: the LEADER trial (9,430 patients), published in 2016, and the TECOS trial (14,735 patients), published in 2015. The former examined the effects of liraglutide on cardiovascular outcomes of T2DM patients, 11 whilst the latter administered the use of sitagliptin for the same objective. 13 In each study, patients at high risk of cardiovascular disease from more than 30 countries were randomly assigned in a 1:1 ratio to be a placebo group or a drug-treatment group (liraglutide subcutaneous 1.8 mg or sitagliptin oral 100 mg). The median follow-up time was 3.5 years for the LEADER trial and 3.0 years for the TECOS trial. Only statistically significant cardiovascular outcomes were included in analyses performed for the study, as presented below (Table 1) .
Costs
Drug costs were calculated from daily doses and unit costs. Daily doses, used in cost calculations, were those in the LIRA-DPP4 trial, 9,10 whilst the unit costs of the drugs were derived from the Royal Government Gazette of Thailand (February 23, 2018 14 ). The daily costs were 160.50 THB (4.96 USD) and 240.75 THB (7.43 USD) for 1.2 mg and 1.8 mg liraglutide, respectively, and 32.68 THB (1.01 USD) for sitagliptin (100 mg/tablet). Costs of cardiovascular events, such as fatal myocardial infarction, non-fatal myocardial infarction, and stroke, were obtained from the study conducted in Thailand. 15, 16 Each cost item was displayed in ).
Analysis
The cost of control of T2DM was defined as the cost of treatment divided by the specific outcome. In part 1, the cost of control was calculated from the cost of individual treatments divided by the percentage of patients achieving the composite endpoint. The ratio of composite endpoint between liraglutide and sitagliptin >1 indicated that liraglutide achieved the composite endpoint greater than sitagliptin did. In part 1, the ratio of cost of control was calculated as the cost of control of liraglutide divided by the cost of control of sitagliptin. The ratio of cost of control >1 indicated the higher cost of liraglutide than sitagliptin treatment to achieve the composite endpoint.
The TECOS trial 13 . Consequently, the magnitude of reductions of incidence rate between the active treatment (either liraglutide or sitagliptin) and placebo groups were quantified. A positive number indicated reduced cardiovascular outcomes with the active treatment group compared with the placebo group. The incidence ratio was also calculated. An incidence ratio of >1 indicated a greater reduction in cardiovascular outcomes with liraglutide compared with sitagliptin. The mathematical equations for calculation were as follows: Incidence rate reduction in liraglutide group=number of events in placebo group-number of events in liraglutide group Incidence rate reduction in sitagliptin group=number of events in placebo group-number of events in sitagliptin group Incidence ratio ¼ incidence rate reduction in liraglutide group incidence rate reduction in sitagliptin group
In addition to cost of control, the ratio of cost of control between cost of control for liraglutide and sitagliptin was calculated. The ratio of >1 indicated the higher cost of liraglutide than sitagliptin treatment. To derive the reduction in incidence rate in the liraglutide group, the difference between the number of events in the placebo group and number of events in the liraglutide group was calculated.
The monetary value of the benefits from reducing the incidence of composite endpoint (death from cardiovascular cause, non-fatal myocardial infarction, and non-fatal stroke) was also calculated by multiplying the proportion of such events, reported in the TECOS 13 and LEADER trials, 11 by their treatment costs. However, the cost of saving life was not included. The difference in total costs incurred between the two drug treatments were calculated as the cost savings.
Results
Part I
Treatment with liraglutide (1.2 and 1.8 mg daily doses) costs 4.91-and 7.37-times more, respectively, than with sitagliptin 100 mg (Table 3 ). However, the 1.8 mg liraglutide treatment resulted in 49% of patients achieving the composite endpoint of T2DM control (HbA1c<7.0%, with no reported hypoglycemia and no body weight gain), the highest percentage among all the treatments. In this respect, liraglutide 1.2 mg and 1.8 mg daily doses were 2.09-and 2.63-times more effective, respectively, compared with sitagliptin 100 mg (Table  1) . Consequently, the cost per controlled patient using (Table 4) . Sitagliptin, in effect, increased death from cardiovascular causes slightly, compared with the placebo (by 0.05 incidents per 100 patientsyear), whereas liraglutide reduced it by 0.40 incidents per 100 patients-year) (P=0.007). Consequently, the incidence ratio could not be calculated. Liraglutide 1.8 mg also reduced incidence of myocardial infarction 3.3-times more than sitagliptin did (compared with their respective placebos). However, incidence of myocardial infarction remained higher with liraglutide than with sitagliptin, although the statistical significance of the result was borderline (P=0.046). 11 Consequently, the cost per event-reduction of myocardial infarction was 2.21-times higher with liraglutide than with sitagliptin (Table 4) . When the economic costs of adverse cardiovascular outcomes that constituted the cardiovascular composite endpoint were taken into account, treatment with liraglutide 1.8 mg reduced such costs by 32,512 THB (1,004 USD) per 100 patients per year compared with the placebo. This was 20,085 THB (620 USD) more than the cost savings from treatment with sitagliptin 100 mg [12,427 THB (384 USD)] (Table 5 ).
Discussion
The significant clinical benefits of liraglutide are substantiated by strong clinical evidence; 11 however, the cost of the drug must also be considered, when comparing it with commonly used incretin-based oral anti-diabetic drugs, such as sitagliptin. Therefore, this study considered both the costs and benefits of the drug, compared with sitagliptin. Part 1 of the study revealed that, once the clinical benefits are included (achieving the composite endpoint: HbA1c<7.0%, no hypoglycemia and no weight gain), the costs of the liraglutide treatments (1.8 and 1.2 mg daily) per controlled patient were 2.35-and 2.80-times higher, respectively, than for sitagliptin 100 mg. This result contrasts with a similar Canadian study 18 that reported lower costs to achieve the same clinical endpoint of liraglutide (1.8 and 1.2 mg daily) compared with sitagliptin (100 mg daily). This may have been due to a smaller difference in the annual medication costs between the two drugs in Canada (liraglutide 1.2 mg is only 1.9-times more expensive than sitagliptin 100 mg, compared with 4.9-and 7.4-times more expensive [1.2 and 1.8 mg/day, respectively) in Thailand]. Therefore, the clinical benefits provided by treatment with liraglutide treatment could outweigh its high medical cost in Canada.
When cardiovascular outcomes are included in the evaluation, 11, 13 liraglutide reduced the incidence rate of major adverse cardiovascular events (MACE) -cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke -by 12.50-times compared to sitagliptin. Ultimately, this meant that for every 1 THB spent on sitagliptin, only Composite endpoint defined as achieving HbA1c<7.0%, no hypoglycemia, and no weight gain. The proportion of each cardiovascular outcome in the liraglutide treatment group was 29.8% for cardiovascular death, 45.2% for nonfatal myocardial infarction and 25.0% for nonfatal stroke while the proportion in the placebo group was 32.7% for cardiovascular death, 43.8% for nonfatal myocardial infarction, and 23.5% for nonfatal stroke. The proportion of each cardiovascular outcome in the sitagliptin treatment group was 42.0% for cardiovascular death, 38.3% for nonfatal myocardial infarction, and 19.7% for nonfatal stroke, while the proportion in the placebo group was 39.3% for cardiovascular death, 39.4% for nonfatal myocardial infarction, and 21.3% for nonfatal stroke.
d Cost incurred from composite endpoint = cost of each cardiovascular outcome*The proportion of that event that occurred. However, cost of cardiovascular death was not included due to limited data. 0.59 THB needs to be spent on liraglutide, to bring about control of a patient in terms of reducing MACE. After converting the lowered incidence rate of cardiovascular composite endpoint outcomes into a monetary value, liraglutide yielded cost savings of 20,085 THB (620 USD) per 100 patients per year compared with sitagliptin. In addition, liraglutide (1.8 mg) reduces mortality due to cardiovascular causes amongst T2DM patients significantly (P=0.007), 11 whereas sitagliptin (100 mg) had no significant effect (P=0.71). 13 If reduction of cardiovascular death is taken into account, the cost of control with liraglutide is much lower than that with sitagliptin. Although liraglutide reduced myocardial infarction more than sitagliptin did, the cost of control ratio was 2.21, indicating that the cost of using liraglutide was more than double that of sitagliptin per event reduction of myocardial infarction.
Several limitations with this study should be discussed, the most notable of which is the absence of a head-to-head clinical trial comparing cardiovascular outcomes between liraglutide and sitagliptin. Although a meta-analysis has been published recently, 19 comparing the effects of sodium-glucose cotransporter 2 inhibitors, GLP-1 receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors on all causes of mortality among T2DM patients, we decided not to use its findings, in terms of cardiovascular outcomes, due to the following reasons. Firstly, most studies included in the meta-analysis did not aim to measure cardiovascular outcomes as the primary endpoint. Of the 14 studies included in the meta-analysis that compared between DPP-4 inhibitors and GLP-1 agonists, fewer than half of them compared between liraglutide and sitagliptin. Therefore, the cardiovascular outcomes of liraglutide and sitagliptin were based on the landmark clinical trials, LEADER 11 and TECOS. 13 Both of these trials enrolled T2DM patients at high risk of cardiovascular disease, even though patients who received the placebo in the LEADER trial 11 were more likely to have cardiovascular events than those in the TECOS trial were. 13 To address this issue, cardiovascular outcomes that occurred when using the two drugs were compared with their respective placebos, and not with each other. Secondly, although death from cardiovascular causes was included among the outcomes that constituted the composite endpoint, there is no data on the monetary value of preventing cardiovascular death in Thailand. Consequently, monetary benefit was calculated from the reduction in non-fatal myocardial infarction and non-fatal stoke only.
Furthermore, in the LEADER trial, 20 liraglutide significantly reduced composite renal outcomes (including death due to renal cause, renal replacement therapy, doubling of serum creatinine, and new onset of macroalbuminuria) (P=0.003); whereas, in the TECOS trial, 13 sitagliptin had no significant effect. When such savings are added to those found by the present study (based on cardiovascular outcomes), the total cost savings would be considerably increased.
Although treatment with liraglutide is expensive relative to other oral anti-diabetic drugs and reimbursement is limited in many healthcare systems, including Thailand, its use when other treatments fail or lead to significant side-effects may be suitable. Other studies 21, 22 have shown that liraglutide reverses pronounced insulin-associated weight gain, decreases insulin requirements, and improves glycemic control in T2DM patients. Such benefits may also result in additional cost savings, which are not included in the present study.
Conclusion
This study has identified the clinical benefits of liraglutide, namely, HbA1c<7.0%, no hypoglycemia, and no weight increase, partially offset in its high price. In addition, when cardiovascular benefits are taken into account in monetary terms, liraglutide yields cost savings. Liraglutide should, therefore, be considered as an appropriate alternative to sitagliptin, particularly for T2DM patients with high cardiovascular risks.
